The IRA: How Public Policy Impacts Innovation

In this KOL Conversation, two AZBio Board Members discuss drug development and the challenges created for health innovators by provisions in the Inflation Reduction Act.


 Note:  This video includes personal perspectives and does not necessarily reflect the positions of the speaker’s  respective organizations. 

Learn More about the Inflation Reduction Act. 

About the Speakers:

Dr. Steve Potts  has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He has a proven track record of success, with 3 of his last 4 companies having returned investors a minimum of 8x (800%)  on their investments. He has been involved in two successful approved drugs, including most recently Roche’s, and is currently bringing a novel mechanism precision oncology drug into clinical trials that has consistently shown sustained complete responses in all hormone receptor positive breast cancer preclinical models tested to date.

Dr. Rafael Fonseca is a hematologist who specializes in the care and research of multiple myeloma and related conditions.   He participates and leads clinical trials that have led to the approval of various drugs for the treatment of myeloma. His efforts include translational research, clinical research and clinical care. Dr. Fonseca led a team of researchers that characterized the clinical implications of genetic markers in myeloma. He also has expertise in myeloma bone disease, prognostic markers, pharmacoeconomics and new drug development. Throughout his training and career, Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.

Posted in AZBio News.